

# Ryan Limbocker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5281966/publications.pdf>

Version: 2024-02-01

29  
papers

1,082  
citations

687335

13  
h-index

610883

24  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1377  
citing authors

#	ARTICLE	IF	CITATIONS
1	A natural product inhibits the initiation of $\hat{1}\pm$ -synuclein aggregation and suppresses its toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1009-E1017.	7.1	231
2	Systematic development of small molecules to inhibit specific microscopic steps of $\hat{A}\hat{1}^242$ aggregation in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E200-E208.	7.1	180
3	Trodusquemine enhances $\hat{A}\hat{1}^242$ aggregation but suppresses its toxicity by displacing oligomers from cell membranes. Nature Communications, 2019, 10, 225.	12.8	111
4	Small-molecule sequestration of amyloid- $\hat{1}^2$ as a drug discovery strategy for Alzheimer's disease. Science Advances, 2020, 6, .	10.3	95
5	Multistep Inhibition of $\hat{1}\pm$ -Synuclein Aggregation and Toxicity <i>in Vitro</i> and <i>in Vivo</i> by Trodusquemine. ACS Chemical Biology, 2018, 13, 2308-2319.	3.4	86
6	Rational design of a conformation-specific antibody for the quantification of $\hat{A}\hat{1}^2$ oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13509-13518.	7.1	61
7	Massively parallel <i>C. elegans</i> tracking provides multi-dimensional fingerprints for phenotypic discovery. Journal of Neuroscience Methods, 2018, 306, 57-67.	2.5	52
8	Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism. Communications Biology, 2020, 3, 435.	4.4	44
9	Impaired Brain Dopamine and Serotonin Release and Uptake in Wistar Rats Following Treatment with Carboplatin. ACS Chemical Neuroscience, 2016, 7, 689-699.	3.5	39
10	Squalamine and Its Derivatives Modulate the Aggregation of Amyloid- $\hat{1}^2$ and $\hat{1}\pm$ -Synuclein and Suppress the Toxicity of Their Oligomers. Frontiers in Neuroscience, 2021, 15, 680026.	2.8	34
11	Squalamine and trodusquemine: two natural products for neurodegenerative diseases, from physical chemistry to the clinic. Natural Product Reports, 2022, 39, 742-753.	10.3	27
12	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. International Journal of Molecular Sciences, 2020, 21, 8651.	4.1	23
13	Localized Drug Application and Sub-Second Voltammetric Dopamine Release Measurements in a Brain Slice Perfusion Device. Analytical Chemistry, 2014, 86, 4151-4156.	6.5	18
14	A rationally designed bicyclic peptide remodels $\hat{A}\hat{1}^242$ aggregation in vitro and reduces its toxicity in a worm model of Alzheimer's disease. Scientific Reports, 2020, 10, 15280.	3.3	15
15	Rationally Designed Antibodies as Research Tools to Study the Structure-Toxicity Relationship of Amyloid- $\hat{1}^2$ Oligomers. International Journal of Molecular Sciences, 2020, 21, 4542.	4.1	12
16	Comparative Studies in the A30P and A53T $\hat{1}\pm$ -Synuclein <i>C. elegans</i> Strains to Investigate the Molecular Origins of Parkinson's Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 552549.	3.7	12
17	Impact of COVID-19 on General Chemistry Education at the United States Military Academy. Journal of Chemical Education, 2020, 97, 2922-2927.	2.3	11
18	Regional Differences in Dopamine Release in the R6/2 Mouse Caudate Putamen. Electroanalysis, 2018, 30, 1066-1072.	2.9	7

#	ARTICLE	IF	CITATIONS
19	A Brain-Permeable Aminosterol Regulates Cell Membranes to Mitigate the Toxicity of Diverse Pore-Forming Agents. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1219-1231.	3.5	7
20	Two human metabolites rescue a <i>C. elegans</i> model of Alzheimer's disease via a cytosolic unfolded protein response. <i>Communications Biology</i> , 2021, 4, 843.	4.4	6
21	Systematic Development of Small Molecules to Inhibit Specific Microscopic Steps of Amyloid-Beta42 Aggregation in Alzheimer's Disease. <i>Biophysical Journal</i> , 2018, 114, 225a.	0.5	2
22	Modulating Amyloid-Beta Aggregation to Reduce the Toxicity of its Oligomeric Aggregates. <i>Biophysical Journal</i> , 2018, 114, 430a.	0.5	2
23	Attenuating the Toxicity of Amyloid-Beta Aggregation with Specific Species. <i>Biophysical Journal</i> , 2017, 112, 494a.	0.5	1
24	Non-Pharmaceutical Interventions and Military Hygiene at the United States Military Academy between 1890 and 1910. <i>Military Medicine</i> , 2020, 185, e2104-e2109.	0.8	1
25	Utilization of Standardized College Entrance Metrics to Predict Undergraduate Student Success in Chemistry. <i>Journal of Chemical Education</i> , 2022, 99, 1725-1733.	2.3	1
26	02: TARGETING AMYLOID FORMATION USING RATIONALLY DESIGNED ANTIBODIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P611.	0.8	0
27	Investigation of Molecular Countermeasures to Modulate the Populations and Toxicity of A $\beta$ <sup>242</sup> Oligomers. <i>Biophysical Journal</i> , 2021, 120, 202a.	0.5	0
28	Therapeutics Against Protein Misfolded Oligomers in Neurodegenerative Diseases. <i>Biophysical Journal</i> , 2021, 120, 286a.	0.5	0
29	Cell Membrane Properties can Mediate the Toxicity of Protein Misfolded Oligomers and Folded Toxins. <i>Biophysical Journal</i> , 2021, 120, 308a.	0.5	0